320 related articles for article (PubMed ID: 30635795)
1. Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.
Li M; Yang Y; Xu C; Wei J; Liu Y; Cun X; Yu Q; Tang X; Yin S; Zhang Z; He Q
AAPS J; 2019 Jan; 21(2):18. PubMed ID: 30635795
[TBL] [Abstract][Full Text] [Related]
2. Enhanced chemo-immunotherapy against melanoma by inhibition of cholesterol esterification in CD8
Li M; Yang Y; Wei J; Cun X; Lu Z; Qiu Y; Zhang Z; He Q
Nanomedicine; 2018 Nov; 14(8):2541-2550. PubMed ID: 30193815
[TBL] [Abstract][Full Text] [Related]
3. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
Li C; Han X
Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
[TBL] [Abstract][Full Text] [Related]
4. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis.
Wang G; Xie L; Li B; Sang W; Yan J; Li J; Tian H; Li W; Zhang Z; Tian Y; Dai Y
Nat Commun; 2021 Sep; 12(1):5733. PubMed ID: 34593794
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
[TBL] [Abstract][Full Text] [Related]
6. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.
Liu H; Weber A; Morse J; Kodumudi K; Scott E; Mullinax J; Sarnaik AA; Pilon-Thomas S
PLoS One; 2018; 13(4):e0196033. PubMed ID: 29694419
[TBL] [Abstract][Full Text] [Related]
7. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration.
Nakamura T; Yamazaki D; Yamauchi J; Harashima H
J Control Release; 2013 Oct; 171(2):216-24. PubMed ID: 23860186
[TBL] [Abstract][Full Text] [Related]
8. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
9. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
10. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
[TBL] [Abstract][Full Text] [Related]
12. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
14. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
[TBL] [Abstract][Full Text] [Related]
16. A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor
Yang Y; Tai X; Shi K; Ruan S; Qiu Y; Zhang Z; Xiang B; He Q
Theranostics; 2016; 6(12):2141-2160. PubMed ID: 27698946
[TBL] [Abstract][Full Text] [Related]
17. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
Tang X; Rao J; Yin S; Wei J; Xia C; Li M; Mei L; Zhang Z; He Q
Eur J Pharm Sci; 2019 Jan; 127():161-174. PubMed ID: 30366077
[TBL] [Abstract][Full Text] [Related]
19. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
[TBL] [Abstract][Full Text] [Related]
20. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
